Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis

Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis

Abstract Background We evaluated organ-specific response rates (OSRRs) to first-line lenvatinib plus anti-PD-1 antibodies in patients with advanced hepatocellular carcinoma (HCC). Methods This retrospective analysis included Chinese patients with unresectable/advanced HCC who received first-line len...

Full description

Bibliographic Details
Main Authors: Cheng Huang, Xiao-Dong Zhu, Ying-Hao Shen, Dong Wu, Yuan Ji, Ning-Ling Ge, Ling-Li Chen, Chang-Jun Tan, Jian Zhou, Jia Fan, Hui-Chuan Sun
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Biomarker Research
Subjects:
Lenvatinib
Carcinoma
Hepatocellular
Liver neoplasms
Immunotherapy
Online Access:https://doi.org/10.1186/s40364-021-00274-z

Internet

https://doi.org/10.1186/s40364-021-00274-z

Similar Items